Celcuity Inc. announced on November 9, 2026, that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for REVTORPYK (gedatolisib) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer harboring a PIK3CA mutation, following progression on or after at least one line of endocrine therapy in the metastatic setting.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 25, 2027. The sNDA is supported by data from Study 2 of the phase 3 VIKTORIA-1 trial, which enrolled patients with PIK3CA-mutated disease.

Key finding

The FDA accepted Celcuity’s sNDA for gedatolisib in PIK3CA-mutated HR+/HER2− locally advanced or metastatic breast cancer. In the phase 3 trial supporting the application, median progression-free survival was 11.1 months with gedatolisib, fulvestrant, and palbociclib versus 5.6 months with alpelisib plus fulvestrant.

Study Design

TrialVIKTORIA-1 Study 2, a randomized, open-label phase 3 study
Population362 patients with PIK3CA-mutated HR+/HER2− locally advanced or metastatic breast cancer whose disease progressed during or after treatment with a CDK4/6 inhibitor plus an aromatase inhibitor
TreatmentGedatolisib plus fulvestrant with or without palbociclib. The control arm received alpelisib plus fulvestrant.
Primary endpointProgression-free survival (PFS) with gedatolisib plus fulvestrant and palbociclib versus alpelisib plus fulvestrant, assessed by blinded independent central review

PFS with the gedatolisib doublet versus alpelisib plus fulvestrant was a secondary endpoint. The FDA previously granted gedatolisib Breakthrough Therapy and Fast Track designations based on preliminary clinical data.

Results and Safety

In results presented at the 2026 ASCO Annual Meeting, median PFS was 11.1 months with the gedatolisib triplet versus 5.6 months with alpelisib plus fulvestrant (hazard ratio, 0.50; 95% CI, 0.37–0.68; P < .0001). Grade 3 treatment-related stomatitis occurred in 16.3% versus 5.3% of patients, respectively. Grade 3 treatment-related hyperglycemia occurred in 2.6% versus 13.8%.

Updated analyses were presented at ESMO 2026. Celcuity’s November 9 announcement focused on the FDA’s acceptance of the application and provided no new efficacy or safety data from the mutant cohort.

Clinical Context

HR+/HER2− breast cancer accounts for approximately 70% of breast cancer cases, and roughly 40% of tumors in this subtype harbor a PIK3CA mutation. Gedatolisib inhibits all four class I PI3K isoforms and both mTOR complexes, mTORC1 and mTORC2. NCI SEER data for 2016–2022 show a five-year relative survival rate of 38.1% among women diagnosed with distant HR+/HER2− breast cancer.

On July 14, 2026, the FDA approved gedatolisib with fulvestrant, with or without palbociclib, for adults with HR+/HER2− locally advanced or metastatic breast cancer without a detected PIK3CA mutation whose disease progressed during or after at least one line of endocrine therapy in the metastatic setting. Approval of the sNDA would extend the indication to patients with PIK3CA-mutated disease.


Sources

  • Celcuity Inc. “Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer.” Press release. November 9, 2026. View source.
  • Hurvitz SA, et al. VIKTORIA-1 Study 2. J Clin Oncol. 2026;44(suppl 17). ASCO abstract
  • Celcuity Inc. Updated results from the PIK3CA-mutated cohort of VIKTORIA-1 at ESMO 2026. October 24, 2026. View source
  • US Food and Drug Administration. Gedatolisib approval announcement. July 14, 2026. View source
  • National Cancer Institute. Female Breast Cancer Subtypes. SEER Cancer Stat Facts. View source